Lambert-Eaton myasthenic syndrome: Clinical characteristics, pathogenesis and tumour association

Lambert-Eaton myasthenic syndrome: Clinical characteristics, pathogenesis and tumour association - LEMS and SCLC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40297

Enrollment

Registered

2013-08-02

Start date

2013-08-12

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LEMS

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis of LEMS Criterion 1 and 2 or 1 and 3 have to be fulfilled 1. Clinical features consistent with LEMS (proximal muscle weakness, reduced tendon reflexes, autonomic symptoms) 2. Abnormalities upon repetitive nerve stimulation (decrement of CMAP amplitude and/or increment after voluntary contraction or high frequency stimulation) 3. Presence of VGCC antibodies;Diagnosis of SCLC Definitive diagnosis of SCLC based on pathology results (either cytology or histology).

Exclusion criteria

Exclusion criteria: * Age

Design outcomes

Primary

Measure	Time frame
Description of epidemiology, clinical characteristics and disease course in LEMS patients. Comparison of the humoral and cellular immune response in LEMS patients and SCLC patients with and without LEMS.	—

Secondary

Measure	Time frame
- Tumour size on lung imaging studies and growth rate upon follow-up. - DELTA-P score tumor prediction score in LEMS patients, diagnosis of SCLC upon follow-up - Presence of other auto-antibodies possibly related to LEMS - Tumour infiltration of SCLC by lymphocytes and macrophages (+- LEMS) - Anti-tumour effect of serum VGCC antibodies and related macrophage and adaptive response in vitro - Presence of specific T cells against tumour-related antigens - Patients' experience with symptomatic medication for LEMS	—

Measure

Time frame

- Tumour size on lung imaging studies and growth rate upon follow-up. - DELTA-P score tumor prediction score in LEMS patients, diagnosis of SCLC upon follow-up - Presence of other auto-antibodies possibly related to LEMS - Tumour infiltration of SCLC by lymphocytes and macrophages (+- LEMS) - Anti-tumour effect of serum VGCC antibodies and related macrophage and adaptive response in vitro - Presence of specific T cells against tumour-related antigens - Patients' experience with symptomatic medication for LEMS

—

Countries

Netherlands

Outcome results